Early Lapatinib-Induced Skin Rash Predicts Better Survival With

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

Epidermal Growth Factor Receptor Inhibitors and Skin Rash

Page 1526 – Cancer Therapy Advisor

EGFR Inhibitors and Cutaneous Complications: A Practical Approach

Clinical practice guidelines for the prevention and treatment of

Number of days from start of lapatinib to onset of rash

Molecular Heterogeneity and Response to Neoadjuvant Human

Frontiers Predicting Lapatinib Dose Regimen Using Machine

Development of prediction tools for diarrhea and rash in breast

Interdisciplinary management of EGFR-inhibitor-induced skin

Lapatinib: Package Insert

Effects of lapatinib monotherapy: results of a randomised phase II

Evolution of Case 2-cutaneous metastasis: (A) before TDM1

Cancers, Free Full-Text

Phase II Study of Predictive Biomarker Profiles for Response

HER2-positive breast cancer and tyrosine kinase inhibitors: the